Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
9.38
USD
|
+1.79%
|
|
-4.67%
|
+15.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
99.63
|
361.6
|
373.5
|
84.56
|
205.7
|
237.4
|
-
|
-
|
Enterprise Value (EV)
1 |
99.63
|
361.6
|
373.5
|
84.56
|
205.7
|
237.4
|
237.4
|
237.4
|
P/E ratio
|
-0.67
x
|
-4.84
x
|
-5
x
|
-1.06
x
|
-2.06
x
|
-2.21
x
|
-3.15
x
|
-7.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.71
x
|
4.09
x
|
182
x
|
32.6
x
|
-
|
-
|
7.73
x
|
2.33
x
|
EV / Revenue
|
5.71
x
|
4.09
x
|
182
x
|
32.6
x
|
-
|
-
|
7.73
x
|
2.33
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.86
x
|
-
|
-
|
-
|
-
|
-1.96
x
|
-2.22
x
|
-2.89
x
|
FCF Yield
|
-116%
|
-
|
-
|
-
|
-
|
-51%
|
-45.1%
|
-34.5%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,196
|
14,148
|
15,182
|
17,508
|
25,268
|
25,308
|
-
|
-
|
Reference price
2 |
16.08
|
25.56
|
24.60
|
4.830
|
8.140
|
9.380
|
9.380
|
9.380
|
Announcement Date
|
3/11/20
|
3/18/21
|
3/28/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
17.46
|
88.52
|
2.053
|
2.596
|
-
|
-
|
30.71
|
101.9
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-132.3
|
-49.36
|
-61.41
|
-72.94
|
-92.08
|
-119.5
|
-110.3
|
-62.77
|
Operating Margin
|
-758.14%
|
-55.76%
|
-2,991.18%
|
-2,809.59%
|
-
|
-
|
-359.31%
|
-61.62%
|
Earnings before Tax (EBT)
1 |
-149.2
|
-67.53
|
-71.2
|
-73.81
|
-87.37
|
-129.9
|
-117.1
|
-54.63
|
Net income
1 |
-149.2
|
-67.73
|
-71.2
|
-73.81
|
-87.37
|
-129.9
|
-117.1
|
-54.63
|
Net margin
|
-854.77%
|
-76.51%
|
-3,468.1%
|
-2,843.3%
|
-
|
-
|
-381.42%
|
-53.63%
|
EPS
2 |
-24.00
|
-5.280
|
-4.920
|
-4.560
|
-3.960
|
-4.242
|
-2.975
|
-1.203
|
Free Cash Flow
1 |
-115.6
|
-
|
-
|
-
|
-
|
-121
|
-107
|
-82
|
FCF margin
|
-662.13%
|
-
|
-
|
-
|
-
|
-
|
-348.42%
|
-80.5%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/11/20
|
3/18/21
|
3/28/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
0.002
|
0.545
|
2.596
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.85
|
-16.51
|
-16.98
|
-21.4
|
-17.71
|
-16.85
|
-19.34
|
-20.29
|
-21.31
|
-31.14
|
-28.95
|
-29.79
|
-30.76
|
-31.54
|
Operating Margin
|
-742,300%
|
-3,029.54%
|
-654.08%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.79
|
-16.48
|
-16.96
|
-21.95
|
-18.09
|
-16.81
|
-15.71
|
-24.28
|
-20
|
-27.37
|
-30.61
|
-31.48
|
-32.02
|
-32.92
|
Net income
1 |
-22.79
|
-16.48
|
-16.96
|
-21.95
|
-18.09
|
-16.81
|
-15.71
|
-24.28
|
-20
|
-27.37
|
-30.61
|
-31.48
|
-32.02
|
-32.92
|
Net margin
|
-1,139,300%
|
-3,024.04%
|
-653.39%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.560
|
-1.200
|
-1.080
|
-1.440
|
-1.080
|
-0.9600
|
-0.9600
|
-1.370
|
-0.7500
|
-1.020
|
-1.155
|
-1.078
|
-1.040
|
-1.020
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/28/22
|
5/9/22
|
8/8/22
|
11/3/22
|
3/14/23
|
5/9/23
|
8/8/23
|
11/8/23
|
3/14/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-116
|
-
|
-
|
-
|
-
|
-121
|
-107
|
-82
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.01
|
0.03
|
0.2
|
-
|
-
|
0.25
|
0.25
|
-
|
Capex / Sales
|
0.04%
|
0.04%
|
9.55%
|
-
|
-
|
-
|
0.81%
|
-
|
Announcement Date
|
3/11/20
|
3/18/21
|
3/28/22
|
3/14/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
9.38
USD Average target price
28.79
USD Spread / Average Target +206.88% Consensus |
1st Jan change
|
Capi.
|
---|
| +15.23% | 237M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|